Literatur
- 1
Hanefeld M.
Primäre Prävention des Typ-2 Diabetes mellitus.
Dtsch Med Wochenschr.
2002;
127
951-952
- 2
Jacob S, Halle M.
Prävention des Typ-2-Diabetes.
Der Bay Int.
2007;
27
6-14
- 3
Jacob S, Leschke M.
Neue Aspekte für den klinischen Alltag - Störungen des Glukosestoffwechsels und kardiovaskuläre
Erkrankungen.
Klinikarzt.
2005;
34
349-353
- 4
Haffner S M, Lehto S, Ronnemaa T. et al .
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic
subjects with and without prior myocardial infarction.
N Engl J Med.
1998;
339
229-234
- 5
Gitt A K, Schiele R, Zeymer U. et al .
Intensive treatment of coronary artery disease in diabetic patients in clinical practice:
results of the MITRA study.
Acta Diabetol.
2003;
Suppl. 2
S 343-S 347
- 6
Gitt A K. et al .
Excessive hospital and one-year-mortality in diabetics compared to nondiabetics with
non-ST elevation myocardial infarction in clinical practice: results of the ACOS-Registry
(abstract).
J Am Coll Cardiol.
2003;
A 41 (Suppl 6)
1191-1192
- 7
Gitt A K, Schiele R, Wienbergen H. et al .
Increased hospital and long-term mortality for non-ST elevation myocardial infarction
in patients with diabetes: results from the ACOS registry.
Eur Heart J.
2003;
24 (Abstract Supplement)
674
- 8
Leschke M, Schwenk B, Bollinger C. et al .
Häufigkeit der Störungen des Glukosestoffwechsels bei Patienten mit koronarer Herzkrankheit.
Clin Res Cardiol.
2006;
95 (Suppl. 1)
1 / 98-1 / 102
- 9
de Vegt F, Dekker J M, Ruhe H G. et al .
Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn
population: the Hoorn Study.
Diabetologia.
1999;
42
926-931
- 10
Barr E L, Zimmet P Z, Welborn T A. et al .
Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus,
impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes,
Obesity, and Lifestyle Study (AusDiab).
Circulation.
2007;
116
151-157
- 11
The Task Force on Diabetes and Cardiovascular Diseases of the European Society of
Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary.
Eur Heart J.
2007;
28
88-136
- 12
Kahn S E, Hull R L, Utzschneider K M.
Mechanisms linking obesity to insulin resistance and type 2 diabetes.
Nature.
2006;
444
840-846
- 13
Berry C, Tardif J-C , Bourassa M G.
Coronary heart disease in patients with diabetes. Part I: Recent advances in prevention
and non-invasive management.
J Am Coll Cardiol.
2007;
49
631-642
- 14
Isomaa B, Almgren P, Tuomi T. et al .
Cardiovascular morbidity and mortality associated with the metabolic syndrome.
Diabetes Care.
2001;
24
683-689
- 15
Eckel R H, Grundy S M, Zimmet P Z.
The metabolic syndrome.
Lancet.
2005;
365
1415-1428
- 16
Hanley A JG, Williams K, Stern M P. et al .
Homeostasis model assessment of insulin resistance in relation to the incidence of
cardiovascular disease: the San Antonio Heart Study.
Diabetes Care.
2002;
25
1177-1184
- 17
Yusuf S, Hawken S, Ounpuu S. et al .
INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27
000 participants from 52 countries: a case-control study.
Lancet.
2005;
366
1640-1649
- 18
Festa A, D'Agostino R, Tracy R P. et al .
Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins
and plasminogen activator inhibitor-1 predict the development of type 2 diabetes:
the insulin resistance atherosclerosis study.
Diabetes.
2002;
51
1131-1137
- 19
Balletshofer B M, Rittig K, Enderle M D. et al .
Endothelial dysfunction is detectable in young normotensive first-degree relatives
of subjects with type 2 diabetes in association with insulin resistance.
Circulation.
2000;
101
1780-1784
- 20
Heitzer T, Schlinzig T, Krohn K. et al .
Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients
with coronary artery disease.
Circulation.
2001;
104
2673-2678
- 21
Ledru F, Ducimetiere P, Battaglia S.
Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study.
J Am Coll Cardiol.
2001;
37
1543-1550
- 22
Natali A, Vichi S, Landi P. et al .
Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcome.
Diabetologia.
2000;
43
632-641
- 23 Tschöpe D, Stratmann B, Standl E. et al .Diagnostik und Therapie von Herzerkrankungen
bei Diabetes mellitus. In: Scherbaum WA (Hrsg). Evidenzbasierte Leitlinie DDG. Aktualisierung
5 / 2006 Auch unter www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/LL_Diabetes_und_Herz_120506.pdf
- 24
Shaw L J, Iskandrian A E.
Prognostic value of gated myocardial perfusion SPECT (review).
J Nucl Cardiol.
2004;
11
171-185
- 25
Jacob S, Halle M.
Verbesserung der kardiometabolischen Prognose - Was können Typ-2-Diabetiker mit einer
Lebensstiländerung erreichen?.
Cardiovasc.
2006;
5
30-33
- 26
Church T S, Cheng Y J, Earnest C P. et al .
Exercise capacity and body composition as predictors of mortality among men with diabetes.
Diabetes Care.
2004;
27
83-88
- 27
Di Loreto C, Fanelli C, Lucidi P. et al .
Make your diabetic patients walk: long-term impact of different amounts of physical
activity on type 2 diabetes.
Diabetes Care.
2005;
28
1295-1302
- 28
The Look Ahead Research Group .
Reduction in weight and cardiovascular disease risk factors in individuals with type
2 diabetes one-year results of the Look AHEAD trial.
Diabetes Care.
2007;
30
1374-1383
- 29
Messerli F H, Mandia G, Conti C R. et al .
Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients
with coronary artery be dangerous?.
Ann Intern Med.
2006;
144
884-893
- 30
Dahlof B, Sever P S, Poulter N R. et al .
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine
adding perindopril as required versus atenolol adding bendroflumethiazide as required,
in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):
a multicentre randomised controlled trial.
Lancet.
2005;
366
895-906
- 31
Lindholm L H, Ibsen H, Dahlof B. et al .
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention
For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet.
2002;
359
1004-1010
- 32 Jacob S, Balletshofer B, Häring H U. Therapie der Hypertonie bei Diabetes mellitus. In:
Schatz H (Hrsg). Diabetologie kompakt. 4. Aufl. Thieme, Stuttgart 2006; 207-214
- 33
Mancia G, De Backer G, Dominiczak A. et al .
2007 Guidelines for the management of arterial hypertension: The Task Force for the
Management of Arterial Hypertension of the European Society of Hypertension (ESH)
and of the European Society of Cardiology (ESC) [In Process Citation].
Eur Heart J.
2007;
28
1462-1536
- 34
American Diabetes Association .
Standards of medical care in diabetes.
Diabetes Care.
2007;
30
S 4-S 41
- 35
Jacob S.
Therapie des kardiometabolischen Syndroms.
Klinikarzt.
2007;
36
43-47
- 36
Gaede P, Vedel P, Larsen N. et al .
Multifactorial Intervention and cardiovascular disease in patients with type 2 diabetes.
N Engl J Med.
2003;
348
383-393
- 37
Roffi M, Topol E J.
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation
acute coronary syndromes.
Europ Heart J.
2004;
25
190-198
- 38
Franklin K, Goldberg R J, Spencer F. et al .
Implications of diabetes in patients with acute coronary syndromes.
Arch Intern Med.
2004;
164
1457-1163
- 39
Svensson A M, McGuire D K, Arahamsson P. et al .
Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in
diabetic patients with acute coronary events.
Eur Heart J.
2005;
26
1255-1261
- 40
Norhammer A, Tenerz A, Nilsson G. et al .
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis
of diabetes mellitus: a prospective study.
Lancet.
2002;
359
2140-2144
- 41
Meier J J, Dreifuß S, Gallwitz B. et al .
Einfluss einer eingeschränkten Glukosetoleranz auf das Langzeitüberleben nach akutem
Myokardinfarkt.
Dtsch Med Wochenschr.
2002;
127
1123-1129
- 42
Bypass Angioplasty Revascularization Investigation (BARI) Investigators .
Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI)
by treatment and diabetic status.
J Am Coll Cardiol.
2000;
35
1122-1129
- 43
Kastrati A, Mehilli J, Pache J. et al .
Analysis of 14 trials comparing sirolimus eluting stents with bare metal stents.
New Engl J Med.
2007;
356
1030-1039
- 44
Spaulding C, Daemen J, Boersma E. et al .
A pooled analysis of data comparing sirolimus-eluting stents with bare metal stents.
N Engl J Med.
2007;
356
989-997
- 45
de Jager J, Dekker J M, Kooy A. et al .
Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular
mortality in individuals with type 2 diabetes: the Hoorn Study.
Arterioscler Thromb Vasc Biol.
2006;
26
1086-1093
, Epub 2006 Mar 2
- 46
Hu F B, Manson J E.
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.
N Engl J Med.
2001;
345
790-797
- 47
Muller S, Martin S, Koenig W. et al .
Impaired glucose tolerance is associated with increased serum concentrations of interleukin
6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors.
Diabetologia.
2002;
45
805-812
- 48
Ryden L, Standl E. et al .
Guidelines on diabetes, prediabetes, and cardiovascular diseases.
Europ Heart J Suppl.
2007;
9 (Suppl. C)
C 3-C 74
- 49
DGPR .
www.dgpr.de/fileadmin/user_upload/DGPR/Leitlinien/RehaLL.pdf. Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen
(DLL-Kard-Reha).
Clin Res Cardiol.
2007;
Suppl 2
III / 1-III / 54
Prof. Dr. med. M. Leschke
Klinik für Kardiologie, Pneumologie und Angiologie · Klinikum Esslingen
Hirschlandstraße 97
73730 Esslingen
Email: m.leschke@klinikum-esslingen.de
